Search results
Showing 556 to 570 of 750 results for adult social
Discontinued Reference number: GID-TA10202
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
interventions for depression and anxiety disorders in adults with mild to moderate learning disabilities:- For adults with...
Source guidance details Comes from guidance Social work with adults experiencing complex needs Number NG216 Date issued
systems and processes are effective and cost effective in changing health and social care practitioners' decision-making and ensuring...
details Comes from guidance Advocacy services for adults with health and social care needs Number NG227 Date issued November
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
circumstances and the risk of dependence: Do individual circumstances such as social distress, low income or limited access to...
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
activities. People with MS who have cognitive problems often engage in fewer social and vocational activities, are less likely to be in...
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
from guidance Transition from children's to adults' services for young people using health or social care services Number...
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.